Dong-Ju Lee received his Bachelor’s degree in Biomedical Science from Cheongju University in 2016 and earned his Master’s degree in Medical Science from the University of Ulsan College of Medicine in 2021. During his graduate studies in the Department of Medical Science, his research focused on establishing in vitro models for myocardial ischemia-reperfusion injury and investigating cellular iron metabolism mechanisms. He successfully developed a novel ischemic simulation model, contributing as a co-first author to peer-reviewed publications in international journals, including the Korean Journal of Physiology and Pharmacology and Free Radical Research. Following his academic training, he worked as a researcher at the Research Institute for Medical Sciences, CHA University Bundang CHA Hospital, where he performed hands-on research investigating the anti-fibrotic efficacy of mesenchymal stem cells and PDE4 inhibitors using human primary intestinal myofibroblast (HIMF) models. He subsequently served as a research scientist in the Bio Research Team at E-Flask, a biopharmaceutical venture company, where he participated in establishing the corporate research facility and conducted in vitro drug discovery screening assays. His expertise spans a comprehensive range of biomedical methodologies, including enzyme-based and cell-based assays, molecular biology techniques, and target validation for various therapeutic areas.